Authors: Margolin, K Synold, T Longmate, J Doroshow, JH

Citation: K. Margolin et al., Methodologic guidelines for the design of high-dose chemotherapy regimens, BIOL BLOOD, 7(8), 2001, pp. 414-432

Authors: Morgan, RJ Synold, T Carr, BI Doroshow, JH Womack, EP Shibata, S Somlo, G Raschko, J Leong, L McNamara, M Chow, W Tetef, M Margolin, K Akman, S Longmate, J

Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332

Authors: Somlo, G Doroshow, JH Synold, T Longmate, J Reardon, D Chow, W Forman, SJ Leong, LA Margolin, KA Morgan, RJ Raschko, JW Shibata, SI Tetef, ML Yen, Y Kogut, N Schriber, J Alvarnas, J

Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598

Authors: Roberts, JD Poplin, EA Tombes, MB Kyle, B Spicer, DV Grant, S Synold, T Moran, R

Citation: Jd. Roberts et al., Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation, CANC CHEMOT, 45(2), 2000, pp. 103-110